Clinical trials: Biliary Tract Neoplasm
Cholangiocarcinoma
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
This study will assess the safety and effectiveness of fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by systemic gemcitabine/cisplatin chemotherapy compared to gemcitabine/cisplatin alone, in…
- Trial name
- RELEASE (NCT04099888)
- Testing
- Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemotherapy
- Where
- 50 sites in United States, Belgium and 12 more
- Volunteers
- 41 people
- Sponsor
- PCI Biotech AS
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00033540
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- 112 sites in United States
- Volunteers
- 57 people
- Sponsor
- SWOG Cancer Research Network
Pancreatic Neoplasms, Bile Duct Carcinoma
Whipple Procedure: Standard of Care vs. Thunderbeat
The Whipple procedure is the standard method for therapy for cancerous tumors, inflammation, and stenosis (narrowing) near the head of the pancreas.
- Trial name
- NCT02204124
- Testing
- Thunderbeat, Standard of care scissors, ligatures, clips, and sutures
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Washington University School of Medicine
Biliary Tract Cancer
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer.
- Trial name
- NCT04163900
- Testing
- NUC-1031, Gemcitabine, Cisplatin
- Where
- 125 sites in United States, Australia and 13 more
- Volunteers
- 773 people
- Sponsor
- NuCana plc
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Biliary Tract Cancer
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
This research is studying the effect of the combination of how two study drugs (Nivolumab and DKN-01) works in people with advanced biliary tract cancer.
- Trial name
- NCT04057365
- Testing
- Nivolumab, DKN-01
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas.
- Conditions
- Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
- Trial name
- NCT03684811
- Testing
- FT-2102, Azacitidine, Nivolumab
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 93 people
- Sponsor
- Forma Therapeutics, Inc.
Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7
TAS-102 in Treating Advanced Biliary Tract Cancers
This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body.
- Conditions
- Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7
- Trial name
- NCT03278106
- Testing
- Laboratory Biomarker Analysis, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with advanced or metastatic cholangiocarcinoma that cannot be removed by surgery.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
- Trial name
- NCT01766219
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Wake Forest University Health Sciences
Cancer of the Gallbladder, Cancer of the Biliary Tract
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
This is a Phase II trial of the combination of oxaliplatin (Eloxatin) and capecitabine (Xeloda), known as XELOX, in participants with unresectable or recurrent cholangiocarcinoma, including carcinoma of the gallbladder or biliary…
- Trial name
- NCT00338988
- Testing
- Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Biliary Tract Neoplasms, Liver Cancer
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
BACKGROUND: Various tumor ablative procedures and techniques have been shown to result in immunogenic cell death and induction of a peripheral immune response.
- Conditions
- Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT02821754
- Testing
- Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma
A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
This an open-label，Non-Randominzed Phase 2 study to evaluate the Safety and Tolerability of SHR-1210 in combination with Apatinib or chemotherapy (FOLFOX4 or GEMOX regimen) in subjects with Advanced PLC.or BTC Participants with…
- Trial name
- NCT03092895
- Testing
- SHR-1210, Apatinib, FOLFOX4
- Where
- 7 sites in China
- Volunteers
- 157 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Liver Cancer, Anxiety Disorder
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
The study intervention consists of the early integration of palliative care services into standard oncology care in an outpatient setting for patients with advanced lung and non-colorectal gastrointestinal malignancies who are…
- Conditions
- Liver Cancer, Anxiety Disorder, Depression, Small Cell Lung Cancer
- Trial name
- NCT02349412
- Testing
- Early palliative care
- Where
- 23 sites in United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Cholangiocarcinoma, Hepatobiliary Neoplasm
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).
- Conditions
- Cholangiocarcinoma, Hepatobiliary Neoplasm, Liver Cancer, Bile Duct Cancer
- Trial name
- NCT01151761
- Testing
- Stereotactic Body Radiotherapy, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Advanced Solid Tumors
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell…
- Trial name
- NCT06024174
- Testing
- BMS-986466, Adagrasib, Cetuximab
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Biliary Tract Cancer (BTC), Colorectal Cancer (CRC)
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
- Conditions
- Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC)
- Trial name
- NCT03314935
- Testing
- INCB001158, Oxaliplatin, Leucovorin
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 149 people
- Sponsor
- Incyte Corporation
Biliary Tract Cancer
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
This protocol for Varlitinib is developed for the treatment of Biliary Tract Cancer. Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth…
- Trial name
- TreeTopp (NCT03093870)
- Testing
- Varlitinib, Capecitabine
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 151 people
- Sponsor
- ASLAN Pharmaceuticals
Biliary Tract Cancer
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer
To investigate efficacy and safety of gemcitabine combined with cisplatin and of gemcitabine alone by comparison in patients with advanced biliary tract cancer
- Trial name
- NCT00380588
- Testing
- gemcitabine, cisplatin
- Where
- 7 sites in Japan
- Volunteers
- 84 people
- Sponsor
- Eli Lilly and Company
Cancer, Solid Tumor
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
The purpose of this study is to determine the safety and tolerability of RXC004 as monotherapy and in combination with Nivolumab in patients with advanced malignancies.
- Trial name
- NCT03447470
- Testing
- RXC004, Nivolumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 46 people
- Sponsor
- Redx Pharma Ltd